Compare INNV & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INNV | PCRX |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2021 | 2010 |
| Metric | INNV | PCRX |
|---|---|---|
| Price | $9.30 | $21.72 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $7.00 | ★ $35.33 |
| AVG Volume (30 Days) | 428.8K | ★ 697.4K |
| Earning Date | 05-18-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | 0.14 | ★ 0.16 |
| Revenue | ★ $853,699,000.00 | $541,533,000.00 |
| Revenue This Year | $12.82 | $6.21 |
| Revenue Next Year | $9.22 | $8.26 |
| P/E Ratio | ★ $64.07 | $138.16 |
| Revenue Growth | 11.76 | ★ 26.04 |
| 52 Week Low | $2.60 | $18.80 |
| 52 Week High | $9.64 | $27.99 |
| Indicator | INNV | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 70.28 | 43.11 |
| Support Level | $5.01 | $20.35 |
| Resistance Level | N/A | $27.24 |
| Average True Range (ATR) | 0.65 | 0.90 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 81.42 | 27.01 |
InnovAge Holding Corp is a healthcare delivery platform comprising multiple participants focused on providing all-inclusive, capitated care to high-cost seniors, many of whom are dual-eligible. Its programs are designed to address two of the pressing challenges facing the U.S. healthcare industry: rising costs and poor outcomes. The purpose of the participant-centered care delivery approach is to improve the quality of care participants receive, while keeping them in their homes for as long as possible and reducing the overutilization of high-cost care settings, such as hospitals and nursing homes. The company manages its business as one reportable segment, PACE.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.